Praxis Precision Medicines reported that ulixacaltamide met primary endpoints in two pivotal Phase 3 trials for essential tremor, prompting plans to prepare an NDA and sending the stock sharply higher. The trials enrolled hundreds of patients across randomized and randomized‑withdrawal designs; Study 1 showed a meaningful improvement on activities‑of‑daily‑living metrics and Study 2 demonstrated maintenance of effect during withdrawal. Praxis said the oral, once‑daily small molecule was generally well tolerated. Lead executives framed the results as the first potential new oral therapy for a condition that affects millions in the U.S. The data package supports an early‑2026 regulatory submission timeline, and Praxis’ market response underscores persistent investor appetite for validated neurology assets. For readers: essential tremor therapies target motor‑control circuits and regulatory filings will hinge on both symptomatic benefit and safety in chronic use.